Treatment of myeloma

QJM: An International Journal of Medicine

Volumn 92, Issue 1, 1999, Pages 11-14

  Smith, M L ^a   Newland, A C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; MYELOMA; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION; UNITED KINGDOM;

EID: 0032896966     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.1.11     Document Type: Review

References (24)

1. Durie BC, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36:842-53.
2. Wheatley J. Which myeloma patients benefit from interferon therapy? An overview of 24 randomized trials with 4000 patients. Br J Haem 1998; 102:140.
3. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood 1968; 31:1-9.
4. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey J, Wilson HE. Treatment for multiple myeloma. JAMA 1969; 208:1680-5.
5. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F, Frieri R, Gallamini A, Gallone G, Giovangrossi P, Grignani F, Lauta VM, Liberati M, Musto P, Neretto G, Petrucci MT, Resegotti L, Pileri A, Mandelli F. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients. J Clin Oncol 1991; 9:444-8.
6. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial treatment in multiple myeloma: no advantage of multi-drug chemotherapy over melphalan-prednisolone. Br J Haem 1990; 74:185-91.
7. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339:200-5.
8. Gregory WA, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
9. Durie BG, Dixon DO, Carter S, Stephens S, Bonnet RJ, Salmon SE, Dabich L, Files JC, Costanzi JJ. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983; 1:453-61.
10. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J. Improved survival of increased risk myeloma patients on combined triple alkylating agent therapy: A study of the CALGB. Blood 1979; 54:13-22.
11. Attal M, Harousseau JL, Stoppa A, Sotto J, Fuzibet J, Rossi J, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
12. Gahrton G, Tura S, Lljungman P, Blade J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, de Laurenzi A, Vam Lint M, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, de Witte T, Volin L. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-20.
13. Bentz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukaemia 1997; 11: 281-3.
14. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, Dammacco F, Pileri A. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322:1430-4.
15. Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, MacLennan IC. MRC trial of interferon-alfa 2b maintenance therapy in first plateau phase of multiple myeloma. Br J Haem 1998; 101:195-202.
16. Lokhorst HM, Meuwissen JA, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haem 1989; 71:25-30.
17. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78:44-9.
18. Niesvizky R, Siegel D, Michaeli J. Biology and treatment of multiple myeloma. Blood Rev 1993; 7:24-33.
19. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haem 1998; 100:317-25.
20. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anaemia associated with multiple myeloma. N Engl J Med 1990; 322:1693-9.
21. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330:484-9.
22. Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79:1130-6.
23. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haem 1996; 92:251-4.
24. Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice G, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 12:4711-18.